Custom vaccine trains immune system to fight breast cancer

NCT ID NCT06435351

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized vaccine made from a patient's own immune cells (dendritic cells) trained to recognize unique proteins from their leftover breast tumor after standard chemotherapy and surgery. The goal is to see if the vaccine is safe and can boost the immune system to prevent the cancer from returning. The study enrolls 16 people with high-risk triple negative breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized neoantigen dendritic cell vaccine
What this could lead to: If this works, it could point toward a new way to prevent breast cancer from coming back in high-risk patients after standard treatment.
What could go wrong: This is a very early, small trial with only 16 people. It is designed mainly to test safety and immune response, not yet to prove the vaccine stops cancer. It may not work or may not be feasible for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.